Latest Monoclonal B-cell lymphocytosis Stories

Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC) have found a combination of drugs to potentially treat chronic lymphocytic leukemia (CLL) more effectively. The research was published online on May 3, 2013, and it will appear as a letter in the journal Leukemia, a publication of the prestigious Nature Publishing Group. The study helps address a basic problem of treating CLL. CLL lives both in the blood in circulation, and in lymph nodes and bone marrow. The former is...

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells. The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels...

Ibrutinib, rituximab deliver a 1-2 punch to patients with few good options A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center. Researchers presented the results today at the 54th annual meeting of the American Society of Hematology (ASH). "This is a patient population with a great...

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). CLL is a blood cancer that causes abnormal white blood cells called lymphocytes to accumulate in the blood, bone marrow, and in the lymph nodes or other organs,...

WHITE PLAINS, N.Y., Aug. 23, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish- and Portuguese-speaking patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) and their families. On Thursday, September 13 from 1:00 to 2:30 PM Eastern Time, Dr. Christopher R. Flowers from the Winship Cancer...

-People newly diagnosed with chronic leukemia must often wait to learn if they have a faster- or slower-progressing form of the disease. -This study identified a molecular marker that quickly helps to distinguish which form a patients has. -The findings could enable patients with aggressive disease to start treatment sooner. Researchers have identified a prognostic marker in the most common form of chronic leukemia that can help to distinguish which patients should start treatment...

CHICAGO, June 4, 2012 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC) announced today updated results from three trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). "This meeting at ASCO has been a continued affirmation of the promising activity and clinical benefit of ibrutinib in CLL. It will be exciting to move this toward definitive Phase III study...

-SMIP-016 is a promising experimental drug that kills chronic leukemia cells. -The drug targets a protein called CD37, but it wasn’t known how this kills leukemia cells. -This study showed unexpectedly that CD37 helps regulate both cell-death and cell-survival signals, explaining how the drug works and how it might be improved. A new study has identified a life-and-death signaling role for a molecule on the surface of the immune cells involved in the most common form of chronic...

-Standard treatment for chronic leukemia is too harsh for many older patients. -Early clinical trials testing indicates that these patients respond well to the experimental drug ibrutinib. -This agent merits further testing as a first-line therapy for older chronic-leukemia patients. The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of older patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase...

ABBOTT PARK, Ill., Aug. 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received 510k clearance from the U.S. Food and Drug Administration for a new in vitro diagnostic test to aid in determining the prognosis of patients with chronic lymphocytic leukemia (CLL), a cancer of the lymphocytes. Abbott's Vysis CLL FISH Probe Kit is the first FDA-cleared CLL test to aid in prognosis. The test detects genetic abnormalities in lymphocytes. Lymphocytes, a type of white blood...